These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17599137)

  • 21. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
    Becker C
    Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRIPS: generic irony.
    Howarth GR
    Br J Gen Pract; 2002 Jan; 52(474):57. PubMed ID: 11791819
    [No Abstract]   [Full Text] [Related]  

  • 23. Preliminary injunctions in generic and branded patent litigation.
    Cohen S; England P
    Expert Opin Ther Pat; 2013 Sep; 23(9):1083-6. PubMed ID: 23855903
    [No Abstract]   [Full Text] [Related]  

  • 24. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE; Ray CJ
    Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 26. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland.
    Timonen J; Karttunen P; Bengtström M; Ahonen R
    Health Policy; 2009 Oct; 92(2-3):116-23. PubMed ID: 19346023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
    Hollis A
    Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
    [No Abstract]   [Full Text] [Related]  

  • 29. . . . and Brazilian AIDS programme threatened by US trade action.
    Int J Epidemiol; 2001 Apr; 30(2):413. PubMed ID: 11369751
    [No Abstract]   [Full Text] [Related]  

  • 30. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 31. Legal challenge to India's patent laws threatens access to generic drugs, says charity.
    Moszynski P
    BMJ; 2011 Sep; 343():d5753. PubMed ID: 21908529
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 33. Reforming Canada's Access to Medicines Regime.
    Esmail LC
    CMAJ; 2007 Jul; 177(3):270. PubMed ID: 17664454
    [No Abstract]   [Full Text] [Related]  

  • 34. Changes to India's patent law may deny cheap drugs to millions.
    Mudur G
    BMJ; 2005 Mar; 330(7493):692. PubMed ID: 15790640
    [No Abstract]   [Full Text] [Related]  

  • 35. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.
    Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection of commercial opportunity.
    Wyllie MG
    BJU Int; 2012 Feb; 109(3):E8-9. PubMed ID: 22243668
    [No Abstract]   [Full Text] [Related]  

  • 37. Countering delays in introduction of generic drugs.
    Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545
    [No Abstract]   [Full Text] [Related]  

  • 38. The production of generic drugs in India.
    Love J
    BMJ; 2011 Mar; 342():d1694. PubMed ID: 21427048
    [No Abstract]   [Full Text] [Related]  

  • 39. Market watch: Sales of biologics to show robust growth through to 2013.
    Goodman M
    Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
    [No Abstract]   [Full Text] [Related]  

  • 40. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
    Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
    Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.